Navigation Links
Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
Date:5/7/2012

LOS ANGELES, May 7, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announced today that it is terminating its previously announced proposed public offering pursuant to a preliminary prospectus supplement and an effective shelf registration statement on file with the Securities and Exchange Commission due to market conditions. 

"The Company intends to pursue alternative financing under more favorable conditions", stated Anthony Cataldo, President & Chief Executive Officer of Genesis Biopharma, Inc. 

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers.  The company's lead product candidate, Contego™, is a ready-to-infuse autologous cell therapy utilizing tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma.  Contego™ is based on a currently available physician-sponsored investigational therapy at the National Cancer Institute, MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for the treatment of Stage IV metastatic melanoma. 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks detailed from time to time in the company's filings with the Securities and Exchange Commission, and represent the company's views only as of the date they are made and should not be relied upon as representing the company's views as of any subsequent date.  The company does not assume any obligation to update any forward-looking statements.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012
2. ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China
3. ThermoGenesis Announces Webcast of Presentation at Roth Capital Conference
4. ThermoGenesis Reports Second Quarter Fiscal 2012 Results
5. Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
6. ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference
7. Canadas First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System
8. Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
9. ThermoGenesis Announces Webcast of Presentation at OneMedForum Conference
10. Genesis Biopharmas Scientific and Medical Advisory Board Welcomes Dr. Steven A. Rosenberg, Chief of the Surgery Branch at the NCI
11. Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... SAN FRANCISCO, Calif. , July 6, 2015 /PRNewswire/ ... global pharmaceutical company, and Oculeve, a development-stage medical device ... disease, today announced that they have entered into an ... all-cash transaction.  Under the terms of the agreement, Allergan ... and commercialization milestone payments related to Oculeve,s lead development ...
(Date:7/6/2015)... China Information Technology, Inc. (the "Company" or "CNIT") (Nasdaq ... exchange, and big data solutions in China ... mobile app for Healthcare One Pass, ushering in a ... The Company jointly hosted the launch ceremony with the ... News Net.   The mobile app for Healthcare ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... hospitals scramble to adopt the patient-centered focus that is ... at improving healthcare in the U.S., LodgeNet Healthcare ... engagement solution that encourages patients to become educated, active ... to interact with patients throughout the entire continuum of ...
... EAST BRUNSWICK, N.J. and EDISON, N.J., June 8, ... today announced they had entered into a broad-based ... controlled release products. Under the terms of the ... develop and manufacture products for Amerigen to commercialize ...
Cached Medicine Technology:LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 2LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 3LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 4Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products 2
(Date:7/6/2015)... ... ... With a new community program in the Livonia, Canton and Plymouth areas, Bowker ... charity campaign to raise funds in support of the health and safety of the ... is a coalition created especially to educate and empower teens, bringing awareness to the ...
(Date:7/6/2015)... ... July 06, 2015 , ... World renowned Los Angeles facial ... their ideal appearance through comprehensive treatment solutions. Individuals that want to make multiple changes ... receive a plan that resolves each of their needs. , "Anytime I see ...
(Date:7/6/2015)... ... 06, 2015 , ... Promero, a leading cloud hosting provider ... IP contact center solution hosted by Promero. Randstad Technologies,a leading talent and ... call center platform. , Promero will implement and manage the private cloud ...
(Date:7/6/2015)... ... July 06, 2015 , ... Diabetes affects many of us and the Glycemic ... have diabetes, the majority of which are Type 2. However, eight million do not ... in three, have prediabetes (abnormally high blood sugar levels). Without reductions in blood sugar ...
(Date:7/6/2015)... ... 06, 2015 , ... The Path of Least Resistance: The Evolution of Capitalism ... the U.S. economy over the past 40 years. The book explores the evolution of ... the book is a time capsule that chronicles the economic development of the United ...
Breaking Medicine News(10 mins):Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2Health News:New Book Brings Reveals The Repercussions Associated With The Global Economy 2
... cancer patients who exhibit limited lymph node involvement may ... neoadjuvant chemotherapy before a mastectomy, according to researchers from ... , The findings were reported today at the ... Radiology and Oncology. , "Radiation after surgery has been ...
... can affect practice behavior in inquiries about patient mood ... study led by University of Rochester Medical Center researchers. ... or attitudes, are loathe to broach sensitive topics such ... professor of psychiatry at the Medical Center and lead ...
... 24 As Senators Barack,Obama and John McCain arrive ... be greeted by AIDS activists from across the,country demanding ... his first 100 days in office., On Friday, ... the debate -,AIDS activists will hold a demonstration and ...
... Cooper University,Hospital in Camden, N.J., has agreed ... interest, to settle allegations that it defrauded ... settlement resolves allegations that the hospital improperly,increased ... reimbursement,from the federal health care program. In ...
... training in 60s, 70s wards off loss that weakens ... -- Strength training can help people build muscle mass to ... age until they reach 80, a new study says. , ... , The Ball State University study, sponsored by a ...
... The U.S. Pharmacopeial (USP) Convention is pleased to ... Material (CRM), Dextromethorphan Hydrobromide. USP recently became the ... Standardization accreditation as producer of chemical CRMs. ... new class of reference standard that ensures improved ...
Cached Medicine News:Health News:Cancer patients who receive neoadjuvant therapy followed by mastectomy may not need radiation 2Health News:Personality can hamper a physician's assessment of depression 2Health News:AIDS Activists from Across the Country Converge on Oxford, Mississippi, to Call on McCain and Obama to Commit to National AIDS Strategy 2Health News:New Jersey Hospital to Pay $3.85 Million to Resolve Allegations of Inflating Charges to Obtain Higher Medicare Reimbursement 2Health News:Boomers Should Add Muscle Before It's Too Late 2
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
The Fluoroskan Ascent, a dedicated microplate fluorometer, offers high sensitivity for a wide variety of fluorometric applications....
... is a fixed wavelength fluorometer for ... emission. The spectral characteristics are specifically ... DNA using the standard Hoechst 33258 ... from the presence of protein, RNA, ...
The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates....
Medicine Products: